Gut microbiota and its implications in small bowel transplantation.
10.1007/s11684-018-0617-0
- Author:
Chenyang WANG
1
;
Qiurong LI
2
;
Jieshou LI
3
Author Information
1. Research Institute of General Surgery, Jinling Hospital, Medical School, Nanjing University, Nanjing, 210002, China.
2. Research Institute of General Surgery, Jinling Hospital, Medical School, Nanjing University, Nanjing, 210002, China. liqiurongjue@126.com.
3. Research Institute of General Surgery, Jinling Hospital, Medical School, Nanjing University, Nanjing, 210002, China. lijieshounju@163.com.
- Publication Type:Journal Article
- Keywords:
acute rejection;
biomarker;
chronic rejection;
gut microbiota;
microbiota-targeted therapy;
mucosal immunity;
small bowel transplantation
- MeSH:
Biomarkers;
Gastrointestinal Microbiome;
Graft Rejection;
immunology;
Humans;
Immunity, Mucosal;
Intestine, Small;
microbiology;
transplantation;
Metagenomics;
Transplantation Tolerance;
immunology
- From:
Frontiers of Medicine
2018;12(3):239-248
- CountryChina
- Language:English
-
Abstract:
The gut microbiota is mainly composed of a diverse population of commensal bacterial species and plays a pivotal role in the maintenance of intestinal homeostasis, immune modulation and metabolism. The influence of the gut microbiota on solid organ transplantation has recently been recognized. In fact, several studies indicated that acute and chronic allograft rejection in small bowel transplantation (SBT) is closely associated with the alterations in microbial patterns in the gut. In this review, we focused on the recent findings regarding alterations in the microbiota following SBTand the potential roles of these alterations in the development of acute and chronic allograft rejection. We also reviewed important advances with respect to the interplays between the microbiota and host immune systems in SBT. Furthermore, we explored the potential of the gut microbiota as a microbial marker and/or therapeutic target for the predication and intervention of allograft rejection and chronic dysfunction. Given that current research on the gut microbiota has become increasingly sophisticated and comprehensive, large cohort studies employing metagenomic analysis and multivariate linkage should be designed for the characterization of host-microbe interaction and causality between microbiota alterations and clinical outcomes in SBT. The findings are expected to provide valuable insights into the role of gut microbiota in the development of allograft rejection and other transplant-related complications and introduce novel therapeutic targets and treatment approaches in clinical practice.
